Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / RHHBY - Amgen advancing Rituxan biosimilar


RHHBY - Amgen advancing Rituxan biosimilar

  • Amgen (NASDAQ:AMGN) and collaboration partner Allergan (NYSE:AGN) announce positive results from a second Phase 3 clinical trial, JASMINE, evaluating biosimilar candidate ABP 798 to the branded product, Roche's (OTCQX:RHHBY) Rituxan (rituximab) in patients with CD20-positive B-cell non-Hodgkin lymphoma. The data showed clinical equivalence as well as comparable safety and immunogenicity.
  • More news on: Amgen Inc., Allergan plc, Roche Holding AG, Healthcare stocks news,
  • Read more ...
Stock Information

Company Name: Roche Holding Ltd ADR
Stock Symbol: RHHBY
Market: OTC
Website: roche.com

Menu

RHHBY RHHBY Quote RHHBY Short RHHBY News RHHBY Articles RHHBY Message Board
Get RHHBY Alerts

News, Short Squeeze, Breakout and More Instantly...